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Background: APOBEC3 (A3) proteins restrict viral replication by cytidine deamination of viral DNA genomes and
impairing reverse transcription and integration. To escape this restriction, lentiviruses have evolved the viral
infectivity factor (Vif), which binds A3 proteins and targets them for proteolytic degradation. In contrast, foamy
viruses (FVs) encode Bet proteins that allow replication in the presence of A3, apparently by A3 binding and/or
sequestration, thus preventing A3 packaging into virions and subsequent restriction. Due to a long-lasting FV-host
coevolution, Bet proteins mainly counteract restriction by A3s from their cognate or highly related host species.
Results: Through bioinformatics, we identified conserved motifs in Bet, all localized in the bel2 exon. In line with
the localization of these conserved motifs within bel2, this part of feline FV (FFV) Bet has been shown to be
essential for feline A3 (feA3) inactivation and feA3 protein binding. To study the function of the Bet motifs in detail,
we analyzed the ability of targeted deletion, substitution, and chimeric FFV-PFV (prototype FV) Bet mutants to
physically bind and/or inactivate feA3. Binding of Bet to feA3Z2b is sensitive to mutations in the first three
conserved motifs and N- and C-terminal deletions and substitutions across almost the complete bel2 coding
sequence. In contrast, the Bel1 (also designated Tas) domain of Bet is dispensable for basal feA3Z2b inactivation
and binding but mainly increases the steady state level of Bet. Studies with PFV Bel1 and full-length FFV Bel2
chimeras confirmed the importance of Bel2 for A3 inactivation indicating that Bel1 is dispensable for basal feA3Z2b
inactivation and binding but increases Bet stability. Moreover, the bel1/tas exon may be required for expression of a
fully functional Bet protein from a spliced transcript.
Conclusions: We show that the Bel2 domain of FV Bet is essential for the inactivation of APOBEC3 cytidine
deaminase restriction factors. The Bel1/Tas domain increases protein stability and can be exchanged by related
sequence. Since feA3 binding and inactivation by Bet are highly correlated, the data support the view that FV Bet
prevents A3-mediated restriction of viral replication by creating strong complexes with these proteins.
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Virus defence proteinBackground
Cellular restriction factors are key players of intrinsic
immunity, which acts against viruses immediately after in-
fection [1]. Restriction factors are constitutively expressed
in cells but their expression can be increased by inter-
ferons produced upon viral infection [2-7]. So far, four
anti-retroviral restriction factors have been functionally* Correspondence: m.loechelt@dkfz.de
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distribution, and reproduction in any mediumcharacterized in detail: APOBEC3, Trim5α, tetherin and
SAMHD1 [8-12]. In addition, several other restriction fac-
tors have been detected by genome-wide screens but
require additional experimental characterization [13,14].
Restriction factors interfere with defined steps in the viral
life cycle, leading to attenuation or complete suppression
of virus replication. By coevolution with host-encoded re-
striction factors, current viruses have achieved mecha-
nisms to circumvent this inhibitory activity. Some viruses,
for instance, have acquired special proteins that directly
counteract restriction factors [1,2,8,12,15]. Due to the
interaction of viral proteins with restriction factors, bothCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tive selection to evade or strengthen, respectively, this
functional interaction [16]. Host-virus coevolution directly
impacts the species-specificity of a given pathogen and is
considered as one of the main factors preventing interspe-
cies virus transmission [2].
APOBEC3 (A3) cytidine deaminases are potent anti-
viral restriction factors. These host proteins deaminate
cytidine residues in single-stranded (ss) DNA intermedi-
ates generated during retroviral reverse transcription,
creating hypermutated genomes with uridine residues [17].
Although considered to deaminate only ssDNA, A3 pro-
teins are also active against double-stranded DNA viruses
such as papillomaviruses, probably due to a transient ex-
posure of ssDNA during replication and/or transcription
[18]. In addition, it has been shown that A3s deaminate ge-
nomes of hepadnaviruses, endogenous retroviruses, retroid
elements and possibly even cellular genes [8,19-22]. To
restrict retroviral replication, A3 restriction factors must be
incorporated into viral particles to edit the forming proviral
DNA in the newly infected cell [23]. In contrast, A3s deam-
inate foamy virus (FV) genomes not only in newly infected
cells, but also in virus-producing cells [15] as reverse tran-
scription of FVs may already occur in virus-producing cells
[24]. In addition, it has been shown that some human A3s
have deaminase-independent activities such as blocking
reverse transcription and integration [25-31]. In fact, A3
proteins with mutated catalytic sites have been shown to be
active against HIV-1 [25,31,32].
The dynamic coevolution of host defences and virus
counter-defence has resulted in a significant expansion
of the A3 locus in higher mammals by distinct gene du-
plication events. In humans, this has led to seven dis-
tinct genes/proteins (A3A, B, C, DE, F, G, H), while only
four single-domain A3 genes are present in cats [33-37].
Additional complexity of the A3 repertoire in cats is
achieved by alternative and complex splicing events of
these genes leading to one two-domain feline A3 (feA3)
proteins; for details, see refs. [33,37,38].
Two classes of retroviral counter-defence proteins
against A3s have been described so far: lentivirus Vif
and FV Bet. Data on how other retroviruses replicate in
the presence of A3 restriction factors is scarce, but indi-
cate that these viruses have developed other means to
avoid A3 packaging [27,39].
The mechanism of A3 inactivation by lentiviral (HIV) Vif
is well characterized. Vif acts as an adaptor protein that
binds to both A3 and ubiquitin ligase complexes consisting
of cullin-5, RING-box 1 and elongins B and C [40]. Thus,
Vif induces the ubiquitination and subsequent degradation
of A3 by the proteasome [40]. It has been shown that N-
terminal regions of Vif bind to huA3G and huA3F while a
SOCS box motif mediates ubiquitin ligase complex binding
[40,41]. Binding of Vif to A3G is species-specific andsubstitution of only a single amino acid in human A3G re-
sults in a mutant that is no longer targeted by HIV Vif [42].
The FV bet genes are expressed by all known exogenous
FVs but are also present in the sloth endogenous FV
(SloEFV) genome, which is at least 100 million years old
[43]. Feline and prototype/primate/human FV (PFV) Bet
have been recently shown to counteract defined A3 pro-
teins of feline and human/non-human primate (NHP) ori-
gin, resp., and protect FV replication in A3-positive cells
[15,44,45]. There is no sequence homology between Bet
and Vif and Bet does not contain the SOCS box motif re-
quired for E3 ubiquitin ligase complex interactions [46]. In
contrast to lentiviral Vif, Bet does not induce A3 degrad-
ation [15,44,47]. Bet is thought to directly bind and pos-
sibly sequester A3 proteins, preventing their incorporation
into viral particles [15,44]. In line with this, Bet is expressed
at high levels in infected cells and animals [48] which may
be a prerequisite for such a stoichiometric reaction.
Bet is an accessory protein of FVs, viruses that display
a complex genetic organization. Together with the essen-
tial Bel1/Tas transactivator of both FV promoters, Bet is
mainly expressed from the internal promoter located in
the 3′end of env [49]. Bet is the product of a splicing event
that fuses the 5′ domain of bel1 to the complete bel2 open
reading frame (ORF). All known FVs encode bet and, as
shown by genome localization, corresponding bet genes
are also present in endogenous FVs [43,50]. A protein
consisting of bel2 only is not expressed in vitro; whether it
is expressed in vivo is still unknown.
Although it has been shown that FFV Bet binds to all
known feA3 proteins, the amino acid residues involved
in binding have yet to be identified. It has been shown,
however, that FFV Bet-MCS, with a mutation in the Bel2
domain of Bet, is incapable of counteracting feA3 and
cannot replicate in A3-positive CrFK cells [15,47,51]. In
this FFV proviral genome, a multiple cloning site (MCS)
had been introduced inside the bel2 ORF, leading to the
alteration of E117L118L119 residues to ASVRRGP [51]. Des-
pite complete sequence conservation in the rest of Bet,
Bet-MCS does not bind or inactivate feA3s, indicating that
the mutated region is important for A3 counteraction
[15,47]. Not surprisingly, the replication of FFV-BBtr,
which contains only a truncated bet gene, is likewise
strongly impaired in the presence of A3s [15,47,51].
FVs are retroviruses that differ from other viruses of this
group in many aspects such as protein processing, mor-
phogenesis, gene expression, and replication [49,52,53].
FVs have not yet been associated with any disease and are
considered apathogenic [54]. This feature makes FVs po-
tential vectors for gene delivery and vaccination [53]. The
known human FV isolates are results of zoonotic trans-
missions of diverse simian FVs to humans [55]. With re-
spect to virus-host coevolution, FV show a very strong
coevolution with their host and related species [56,57].
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pects of vector development, host-virus coevolution and
the potential of interspecies transmission to other hosts,
including humans [54].
In this study, we analyzed the functional interaction
between FFV Bet and feA3 restriction factors as a model
for the situation in humans and NHPs, since the feA3
repertoire is less complex than that of these species.
Using bioinformatics and reverse genetics, we identified
conserved motifs in Bet and tested their importance. We
identified the bel2 sequence of Bet as the essential deter-
minant for A3 inactivation. Moreover, this study shows
that nearly the entire FFV Bel2 domain is required for
feA3 binding and inactivation, supporting the view that
Bet inactivates feA3 by creating strong complexes with
this restriction factor [44,45,47].
Results
Bet contains six conserved motifs
All known FV Bet proteins consist of the N-terminus of
Bel1 and the complete Bel2 sequence. However, sequence
homology between Bet proteins of different FVs is very lowFFVBet (67) LPILSPYVM   
BFVBet (70)   LPVLSPYPL  
EFVBet (76) LPVISLFPI  
PFVBet (131) LPVVTPWPM
SFVBet (134)  LPVVTPWPL
SloEFVBet(76) IPATTLFPL
Consensus     LPVVSPYPL
Sequence         LT F M
I  W
(121) PGIGLVQI   























Figure 1 Bet proteins of different FVs contain six conserved motifs. (A
bel2 genes are localized between env and the 3′LTR. The Bet protein is a p
(B) Bioinformatics using the MEME program identified six conserved motifs
and the sequences are given below as well as the consensus sequence. Nu
motifs. In EFV Bet motifs 2 and 3 are found in reversed order. Motifs and re
conservation, such as motifs 4 and 6 and residues flanking motif 3, are rep
bovine FV; EFV, equine FV; PFV, prototype/primate/human FV; SFV, simian F[49]. To identify any possible conserved motifs amongst
different Bet proteins, we performed bioinformatics using
the MEME program, which searches for repeated amino
acid patterns in given sequences [58]. Six conserved motifs,
all localized within Bel2, were identified in the Bet proteins
of bovine (BFV), equine (EFV), simian (SFV) FVs, FFV,
PFV and SloEFV (Figure 1). MEME detected four motifs
with standard settings (shown in black, motifs 1, 2, 3, 5);
two additional motifs (4 and 6, marked in gray letters) were
identified by searching with only the bel2 sequences and
using slightly modified parameters. The first five motifs are
also conserved in the predicted Bet sequence of SloEFV,
although the third and fifth motifs from SloEFV appear to
be shorter than the corresponding motifs in other Bet
proteins (Figure 1). In EFV Bet, the positions of the second
and the third motifs are swapped with respect to the corre-
sponding motifs in the other FV Bet proteins.
The Bel2 part of FFV Bet is sufficient for feA3Z2b binding
and inactivation
It was previously shown that FFV Bet binds and inacti-
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) Genome organisation of FVs. The regulatory and accessory bel1 and
roduct of a spliced transcript and consists of Bel1 and Bel2 parts.
localized in Bel2. Motifs are represented as gray boxes in the figure
mbers in brackets indicate the position of the first amino acid of the
sidues that were not experimentally studied due to low degrees of
resented in light shading and font, respectively. FFV, feline FV; BFV,
V; SloEFV, sloth endogenous FV.
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tions, N-terminal Bet deletion mutants were constructed
(Figure 2A). Eukaryotic expression clone Bel2ORF en-
compasses the whole bel2 ORF, while Bel2ATG starts
with the first start codon inside bel2 which is not con-
served among known FVs. Bel2ORF contains all six con-
served motifs, while Bel2ATG and mutants BetΔN82
and BetΔN92 lack the first motif.Figure 2 Bet and Bel2ORF suppress feA3Z2b-mediated restriction. (A)
deletion mutants. Dark and light gray boxes represent the different MEME
downstream N-terminal Bet deletion mutants do not contain the first cons
deletion mutants. (B) HEK293T cells were cotransfected with 4 μg of pCF-B
deletion mutant expression plasmids as indicated in the legend. pcDNA wa
determined in triplicate using the FeFab titration assay and are presented a
deviations. Labels below the columns indicate cotransfected clones. The lin
column shows the viral titer in the absence of feA3Z2b, the second, in the
presence of feA3Z2b and the coresponding Bet clones, as indicated in the
expression plasmid yielded similar levels of feA3Z2b counteraction. In both
deletion mutants did not counteract feA3Z2b-mediated restriction. (C) 40 μ
immunoblotting. Bet proteins were detected with the FFV Bet- specific seru
shown). (D) Densitometric analysis of the relative levels of Bet protein expr
legend indicates the amount of expression plasmid used to obtain correspWe tested the ability of the mutants to bind to and/or
inactivate feA3Z2b, the feA3 with the highest restriction
potential against Bet-deficient FFV (FFV-BBtr) [33,47,51].
HEK293T cells were cotransfected with pCF-BBtr, the
empty vector pcDNA, or pcfeA3Z2b-HA, and increasing
amounts of plasmids encoding either wt or mutant Bet
(Figure 2B). Two days post transfection (d.p.t.), viral
infectivity was determined by titration using FeFab cells.Schematic representation of full-length Bet and N-terminal Bet
motifs in Bet. Bet and Bel2ORF contain all six conserved motifs, while
erved motif. Numbers indicate the first and the last amino acids of the
Btr, 0.8 μg pcfeA3Z2b-HA, and increasing amounts of wt Bet and Bet
s used to compensate for different plasmid amounts. Viral titers were
s mean values of three measurements; error bars represent standard
e above the columns indicates the presence of feA3Z2b. The first
presence of feA3Z2b. The other columns show the titer in the
figure. 0.7 μg of Bet expression plasmid and 5.6 μg of Bel2ORF
cases, the titer increased more than 1 log. The other N-terminal
g of protein of transfected HEK293T cells was used for
m. Proper loading was confirmed by detecting β-actin (data not
ession. Wt Bet at 5.6 μg of transfected DNA was set to 100%. The
onding protein amounts.
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of viral titer. Wt Bet efficiently counteracted this restric-
tion in a dose-dependent manner. The highest concentra-
tion of Bel2ORF partially increased viral titer in the
presence of feA3Z2b, while shorter deletion mutants did
not have any effect on the viral titer. The presence of Bet
in cell lysates was confirmed by immunoblotting with an
FFV Bet-specific serum (Figure 2C). Levels of Bet deletion
mutants were lower relative to the level of wt Bet, indica-
ting instability of the deletion mutants (Figure 2C and D).
As inactivation of feA3Z2b by Bet is concentration-
dependent, the lower potential of Bel2ORF to counteract
feA3Z2b may be due to the lower steady state of deletion
mutants. As shown in Figure 2 panels B and D, at 0.7 and
5.6 μg transfected plasmid encoding Bet or Bel2ORF, re-
spectively, slightly increased amounts of Bel2ORF protein
resulted in comparable restoration of infectivity of the bet-
deficient FFV genome in the presence feA3Z2b. Both wt
and truncated Bet were detected with similar efficacy by
the Bet antiserum and the V5 tag antibody, shown by
comparative immunoblotting (Additional file 1).
The ability of the truncated Bet proteins to bind feA3Z2b
was tested in pulldown assays with bacterially expressed
glutathione-S-transferase (GST) or GST-tagged feA3Z2b
and lysates from HEK293T cells expressing wt or mutant
Bet, as described previously [47]. Levels of N-terminal Bet
deletion mutants were increased by supplementing the cell
culture medium with 8 mM sodium butyrate. BoundFigure 3 Bet and Bel2ORF bind to feA3Z2b. Bet and Bet N-terminal dele
with GST or GST-feA3Z2b. Immunoblot analysis was performed with Bet-sp
the GST and GST-feA3Z2b fusion proteins (lower panel). Cell lysates (CL) of
expression of wt and mutant Bet proteins. In addition to wt Bet, Bel2ORF w
bands have ‘shades’ (lower panel). Symbols below the image indicate the pproteins were precipitated using glutathione-coupled beads
and detected by immunoblotting. In addition to wt Bet,
known to bind to feA3Z2b [15,47], Bel2ORF was efficiently
precipitated with feA3Z2b (Figure 3). Although low inten-
sity bands are present in the case of Bel2ATG and
BetΔN82, they were not reproducible and therefore con-
sidered to be unspecific. To confirm proper setup of the
assays, the presence of similar amounts of GST and GST-
feA3Z2b was confirmed with an SV40 tag-specific antibody
(Figure 3 lower panel).
C-terminal Bet deletion mutants do not counteract
feA3Z2b-mediated restriction
To determine the minimal Bet sequence required for A3
inactivation, C-terminal deletion mutants were constructed
(Additional file 2A). In transfected cells, the engineered
proteins were present at only very low levels and thus,
functional studies were conducted in the presence and
absence of the proteasome inhibitor ALLN (Additional
file 2B). HEK293T cells were transfected with pCF-BBtr,
feA3Z2b, and wt or mutant Bet constructs. Cultures were
treated for approximately 24 h with 25 μM of the prote-
asome inhibitor ALLN and tested for their ability to coun-
teract feA3Z2b restriction. Both V5-tagged and untagged
full-length Bet but none of the C-terminal Bet deletion
mutants were able to inactivate feA3Z2b in the presence of
ALLN or DMSO (solvent control) (Additional file 2B). The
levels of wt Bet and wt Bet-V5 proteins did not change intion mutants were expressed in 293T cells and pulled down either
ecific serum (upper panel) and an SV40 tag-specific antibody to detect
transfected cells were analyzed in parallel to confirm proper
as pulled down with GST-feA3Z2b. Due to high protein levels, some
resence (+) or absence (−) of GST or GST-feA3.
Slavkovic Lukic et al. Retrovirology 2013, 10:76 Page 6 of 20
http://www.retrovirology.com/content/10/1/76the presence of ALLN, while the level of C-terminal de-
letion mutants increased due to proteasome inhibition
(Additional file 2C).
The feA3Z2b binding ability of the C-terminal deletion
mutants was also tested in pulldown assays. None of the
C-terminal deletions bound to feA3Z2b, despite increased
expression levels in transfected cells due to sodium butyr-
ate addition (Additional file 2D).
PFV Bet does not counteract or bind to feline A3Z2b
To circumvent the problems of the low stability of trun-
cated FFV Bet proteins, we constructed chimeric FFV-
PFV proteins. Bet proteins from different FVs are known
to counteract A3s from cognate species but not from dis-
tantly related species. For instance, it has previously been
shown that FFV Bet does not bind to human A3s [15] and
that PFV Bet does not inactivate murine A3 [44,45]. We
therefore first determined whether PFV Bet binds or inac-
tivates feA3Z2b. HEK293T cells were cotransfected with
pCF-BBtr, pcfeA3Z2b-HA or pcDNA, and plasmids ex-
pressing FFV or PFV Bet. As shown in Figure 4A, viral ti-
ters determined two d.p.i. decreased in the presence of
feA3Z2b and were completely rescued by FFV Bet while,
as anticipated, PFV Bet did not show anti-feA3 activity.
Since PFV Bet bound to glutathione beads incubated
with GST (data not shown), the pulldown assay described
above was not suitable for studying PFV Bet–feA3Z2b
interactions, we thus used coimmunoprecipitation (co-IP)
assays instead. HEK293T cells were cotransfected with
pcfeA3Z2b-HA and plasmids expressing PFV or FFV Bet.Figure 4 PFV Bet does not counteract feA3Z2b. (A) HEK293T cells were
6 μg of plasmid expressing wt FFV or PFV Bet. Viral titers were determined
3 logs. Unlike FFV Bet, which completely rescues the viral titer, PFV Bet did
the presence of feA3Z2b. For co-IP experiments, 293T cells were cotransfec
(B) or PFV Bet (C). Two d.p.t., cell lysates (CL) were subjected to co-IP with
Bet but not PFV Bet proteins were detected by immunoblotting using mon
against PFV Bet, respectively. feA3Z2b-HA, along with a lower molecular we
samples using anti-HA IgG.Two d.p.t., co-IP was performed with monoclonal anti-
HA IgG. Precipitated proteins were detected by immuno-
blotting. Unlike FFV Bet, PFV Bet did not
coimmunoprecipitate with feA3Z2b-HA (Figure 4B and C).
Immunoblotting with anti-HA IgG showed the presence of
feA3Z2b-HA and an unspecific band of lower molecular
mass (Figure 4B and C, lower panel). Incubation of cell ly-
sates with beads only (without antibody, mock co-IP) did
not result in unspecific feA3Z2b-HA precipitation.
Chimeric FFV-PFV Bet proteins containing almost the
entire FFV Bel2ORF bind and inactivate feA3Z2b
To stabilize FFV Bet deletion mutants, eleven chimeric
FFV-PFV Bet proteins, equivalent to the Bet deletion mu-
tants described above, were constructed. In these chimeric
proteins, deleted parts of FFV Bet were substituted by the
equivalent parts of PFV Bet (Figure 5).
Both PFV and FFV Bet consist of Bel1 and Bel2 regions
(Figure 5A), though the sizes of Bel1 regions of FFV and
PFV Bet differ greatly, between 31 and 88 amino acids. In
order to mimic this situation, three chimeric proteins
containing the full FFV Bel2ORF and different lengths of
PFV Bel1 were cloned as described in Methods. FFV-PFV
CH1 contains the first N-terminal 39 amino acids of PFV
Bel1 fused to the FFV Bel2ORF and is still 8 amino acids
larger than the FFV Bel1 part but maintains a predicted
extended secondary structure in the PFV sequence (data
not shown). FFV-PFV CH2 contains PFV Bel1 and four
additional residues from PFV Bel2 to avoid deletion of
a predicted alpha helix in PFV Bet (data not shown).cotransfected with 4 μg of pCF-BBtr, 0.8 μg pcDNA or pfeA3Z2b, and
two d.p.t. In the presence of feA3Z2b, FFV-BBtr titers decreased about
not counteract feA3Z2b activity. The line above the graph indicates
ted with 6 μg of plasmid expressing feA3Z2b-HA and 12 μg of FFV Bet
monoclonal mouse anti-HA IgG or beads only (mock). Precipitated FFV
oclonal V5 tag-specific antibody and polyclonal hyperimmune sera
ight band that also appeared in mock samples, was detected in all
Figure 5 Chimeric FFV/PFV Bet proteins. (A) Schematic structure of FFV Bet and PFV Bet (blue shading). Conserved motifs are represented as
gray boxes for FFV Bet and black boxes for PFV Bet. The Bel1part consists of 31 amino acids in FFV Bet and 88 amino acids in PFV Bet. FFV Bet
contains 387 amino acids and PFV Bet, 482 amino acids. (B) FFV-PFV CH1 to CH6 are chimeras of N-terminal parts of PFV Bet and central and
C-terminal parts of FFV Bet. (C) FFV-PFV CH7 to 11 are chimeras of N-terminal parts of FFV Bet and central and C-terminal parts of PFV Bet. White
shading represents FFV Bet-derived sequences and blue shading, PFV Bet. Numbers indicate positions of the first and the last amino acid derived
from PFV and FFV Bet. For example, CH1 is composed of the first 39 residues of PFV Bet and residues 33–378 of FFV Bet. A green box at the end
of each protein represents the V5 tag.
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directly to FFV Bel2ORF. FFV-PFV CH4 to 6 contain
shorter C-terminal FFV Bet and longer N-terminal PFV
Bet segments, while chimeric proteins CH7 to 11 are equiva-
lent to FFV Bet C-terminal deletion mutants (Figure 5C).
All chimeric proteins were V5-tagged to facilitate proper
protein detection (Figure 5B and C).
To determine whether chimeric proteins CH1 to 6 in-
activate feA3Z2b, HEK293T cells were cotransfected with
pCF-BBtr, pcfeA3Z2b-HA, and plasmids encoding either
wt PFV Bet, wt FFV Bet, or one of the chimeric FFV-PFV
Bet CH1 to CH6 proteins. Viral titers determined 2 d.p.t.
are shown in Figure 6A. As shown before, PFV Bet did
not counteract feA3Z2b activity, while chimeric proteins
CH1 to 3, containing the full-length FFV Bel2ORF anddifferent PFV Bel1 sequences, fully restored FFV titers to
levels similar to wt Bet (Figure 6A). Bet chimeras 4 to 6,
with N-terminal FFV Bel2 sequences replaced by those
from PFV, were non-functional and did not suppress
feA3Z2b restriction.
FFV-PFV chimeric proteins CH7 to 11, carrying C-
terminal PFV sequences of decreasing size were charac-
terized as described above. Only FFV-PFV Bet CH11,
carrying a short and obviously non-conserved C-terminal
PFV Bet fragment, was functionally active against feA3Z2b.
The presence of proteins in cell lysates was confirmed
by immunoblotting with the V5 antibody. Figure 6B and
6D show that the levels of chimeric proteins were com-
parable or slightly lower than those of wt FFV Bet. The
PFV Bet antiserum efficiently detected full-length Bet but
Figure 6 The Bel1 domain and the C-terminal 22 amino acids of FFVBet can be replaced by PFV Bet sequences without loss of
function. HEK293T cells were cotransfected with 4 μg pCF-BBtr, 0.8 μg pcDNA or pfeA3Z2b, and 6 μg of plasmid expressing wt FFV Bet, PFV Bet
or chimera, as indicated in the picture. (A, C) Two d.p.t., titration was performed and viral titers are represented as mean values of three
independent experiments. Error bars represent standard deviations. In the presence of feA3Z2b, the FFV-BBtr titer decreased more than two logs.
Unlike FFV Bet, which completely rescued titers, PFV Bet did not counteract feA3Z2b activity. Chimera CH1, 2, 3, and 11 completely restored the
viral titer in the presence of feA3Z2b (indicated by the line above the graphs). (B, D) FFV Bet and chimeric Bet were detected with anti-V5 IgG
while PFV Bet was detected with a PFV Bet-specific serum. Anti-HA IgG was used for feA3Z2b-HA detection, rabbit anti-matrix serum for Gag
detection, and anti-β-actin IgG as a loading control.
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trast, CH6 to CH9 were detectable only upon extended
exposure (not shown).
Binding of chimeric FFV-PFV Bet proteins to feA3Z2b
was studied by co-IPs as described above. As shown in
Figure 7A and B, only FFV-PFV chimeric proteins CH1,
2, 3 and 11 coimmunoprecipitated with feA3Z2b-HA.
Importantly, unspecific binding to the beads (mock co-
IP) was not observed. Proper set up of the assay was
confirmed by detection of feA3Z2b-HA (Figure 7, la-
belled α-HA in parts A and B).Identification of critical Bet residues by alanine scanning
mutagenesis of conserved motifs
To identify functionally important amino acids in the
conserved Bet motifs, site-directed alanine scanning mu-
tagenesis was performed. Amino acids in the conserved
motifs or in flanking sequences were substituted by ala-
nine as described in Methods and indicated in Figure 8,
resulting in 20 FFV Bet mutants carrying one to three
amino acid substitutions each. Although these Bet mu-
tants are not classical deletion mutants, Δ symbols were
used to facilitate labelling of these substitutions.
Figure 7 FFV-PFV CH1, CH2, CH3 and CH11 bind to feA3Z2b-HA. 293T cells were cotransfected with 6 μg of plasmid expressing feA3Z2b-HA
and 12 μg of one of the chimeric protein expression plasmids (A, N-terminal chimera CH1 to CH6; B, C-terminal chimera CH7 to CH11) or pcDNA,
as indicated in the picture. Two d.p.t., cell lysates (CL) were subjected to co-immunoprecipitation (co-IP) with monoclonal anti-HA IgG or beads
only (mock). Precipitated proteins were detected by immunoblotting. feA3Z2b-HA was detected with an anti-HA monoclonal antibody in each
sample, as expected. A lower molecular weight band that was also detected is considered unspecific, as it also appeared in mock samples.
Hatched lines mark empty lanes used to separate individual experiments. Chimeric proteins were detected with anti-V5 IgG. In addition to FFV
Bet, CH1, 2, 3, and 11 were coimmunoprecipitated by feA3Z2b.
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ectly behind the mutated part of FFV Bet-MCS, in which
an MCS had been inserted inside bel2 [51]. The MCS
introduction resulted in the substitution of three and
addition of four amino acids. Although the rest of Bet
remained unchanged, Bet-MCS did not have anti-feA3
activity and did not bind to feA3 [15,47,51]. We there-
fore proceeded to more carefully characterize the second
conserved motif together with these flanking sequences.
Functional feA3 inactivation and binding studies by
GST-feA3Z2b pulldown were performed to determine
whether mutant Bet proteins inactivate and/or bind
feA3Z2b, as described above. The results are summarized
in Figure 8 and provided in Additional files 3 and 4. As
indicated in Figure 8, most mutations in or close to thefirst, second, or third motifs were detrimental to both Bet
functions, while all 3 amino acid replacement mutants of
the fifth motif displayed a wt phenotype with respect to
feA3 inactivation and binding. Moreover, FFV Bet func-
tion was not impaired by single amino acid changes, while
double amino acid mutations in motif 2 resulted in loss of
function (Figure 8 and Additional file 3). In fact, BetΔV
and BetΔP were both functionally active but the double
mutant BetΔVP, in which both amino acids are replaced
by alanine, was completely incapable of binding and
counteracting feA3Z2b. As indicated in Figure 8 and
shown in the Additional file 4, all mutants capable of
functionally inactivating feA3Z2b also bound to this re-
striction factor in pulldown assays. In addition, BetΔLTM
where mutations are outside of motif 2 and BetΔI where
Figure 8 Site-directed mutagenesis of the first, second, third and fifth conserved Bet motif. FFV Bet contains 387 amino acids and consists
of Bel1 and Bel2 sequences as indicated. Conserved motifs are represented as gray boxes and conserved motif 1, 2, 3 and 5 are underlined.
Motifs 4 and 6 were not analyzed. Alanine residues that substitute the original residues are marked in bold. Numbers in brackets indicate the
positions of the first amino acid in a given sequence. Mutations that did not impair Bet functions are marked with (+) and bolded names. Grey
(+) signs indicates incomplete restoration of FFV titers by certain mutants.
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to feA3Z2b and partially inactivated this restriction factor.
This attenuated phenotype was reproducibly detectable
(data not shown). Moreover, BetΔGPL induced only a
minor increase of the FFV titer (Additional file 3C) and
it was not pulled down with GST-feA3Z2b (Additional
file 4), which may indicate the low sensitivity of the pull
down assay used. However, immunoblotting data show
that protein expression levels of the Bet mutants were
comparable to or slightly lower than wt Bet (Additional
file 3D, E and F). Therefore, the lack of feA3Z2b coun-
teraction by non-functional Bet mutants (in particular
BetΔGPL) was not simply the consequence of low pro-
tein amounts.
In general, the binding properties of Bet substitution
mutants were found to correlate well with their ability to
inactivate feA3Z2b, although there were differences in
the potential of individual mutants to inactivate feA3Z2b
(Additional file 4).
Mutant and wt Bet are localized in the cytoplasm and
colocalize with feA3Z2b and feA3Z2a
Subcellular localization of mutant Bet proteins and their
potential colocalization with feA3s were studied by in-
direct immunofluorescence (IIF) of paraformaldehyde-
fixed HeLa cells using confocal microscopy. Bet was
detected with an FFV Bel2-specific serum and is shown
in red, while feA3Z2b was labeled with monoclonal
anti-HA IgG and is shown in green (Figure 9). Both
feA3Z2b-HA and wt Bet predominantly localize to the
cytoplasm and, in cells coexpressing both proteins,
there is strong colocalization throughout the cytoplasmwithout any indication of a Bet- or feA3Z2b-mediated
relocalization of their corresponding binding partner.
This (apparent) colocalization pattern indicates that the wt
Bet–A3 complexes do not aggregate in specific regions of
the cell but are rather evenly distributed throughout the
cytoplasm. Nonfunctional mutant Bet proteins (BetΔLPI,
BetΔCDP, FFV/PFV Bet CH4) were, similarly to wt Bet,
also evenly distributed in the cytoplasm. In cells co-
expressing these nonfunctional Bet mutants and feA3,
there are regions of strong colocalization. However,
colocalization detected by confocal microscopy does not
prove the interaction of the two proteins but indicates
that the two proteins have the same spatial occupancy
within the cytoplasm. Based on these data, we conclude
that the lack of feA3 inactivation by Bet mutants is not
the consequence of the physical distance between both
proteins.
Since feA3Z2a had been shown in independent studies
to localize to the nucleus and the cytoplasm, we analyzed
the colocalization of this feA3 isoform with wt Bet and
some of the Bet mutants (Figures 10 and 11). In cells
transfected only with V5-tagged wt Bet, Bet is predomi-
nantly found in the cytoplasm (Figure 10B), while in cells
transfected with feA3Z2a, feA3Z2a localizes in both the
nucleus and in the cytoplasm (Figure 10A). In most cells
that express both wt Bet and feA3Z2a, these two pro-
teins consistently colocalize in both compartments,
meaning that Bet is recruited to the nucleus by feA3Z2a
(Figure 10C). In addition, in some cells expressing both
proteins, feA3Z2a and wt Bet predominantly localized
in the cytoplasm (Figure 10D). Functional FFV-PFV Bet
CH1 showed similar colocalization with feA3Z2a as wt
Figure 9 Colocalization of feA3Z2b with wt and mutant Bet proteins. HeLa cells were transfected with plasmids encoding HA-tagged
feA3Z2b-HA (A) and/or Bet expression plasmids (B – G) as indicated on the right side of the image. feA3Z2b-HA was detected with HA tag-
specific antibody (green), wt and mutated FFV Bet were detected by an FFV Bet-specific serum (red) and nuclei were stained with Hoechst 33342
(blue). The merge of feA3Z2b and Bet staining is shown in the right-hand column. feA3Z2b (A, C, E, G), wt (B, C) and mutant Bet proteins
(D – G) are predominantly localized in the cytoplasm. Inserted bars represent 5 μm.
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mutants tested were not recruited to the nucleus by
feA3Z2a (Figure 11).
Discussion
A3 proteins are cellular restriction factors that deaminate
cytidine residues in ssDNA [8,19,34]. Two retroviralproteins that counteract A3 restriction factors have
been described so far in detail: lentiviral Vif and FV Bet
[8,15,44]. These two proteins counteract the A3 activity
in different ways. While Vif induces proteasomal deg-
radation of A3s [40,59-62], FV Bet does not change the
steady state level of A3s [15,44,47]. It is assumed that
Bet counteracts the activity of A3s by forming stable
Figure 10 Colocalization of feA3Z2a with functional Bet proteins. HeLa cells were transfected with a plasmid encoding HA-tagged feA3Z2a-
HA (A) and/or Bet expression plasmids (wt Bet or FFV-PFV Bet CH1, B – H), as indicated on the right. feA3Z2a-HA was detected with HA tag-
specific antibody (green), FFV Bet was detected by an anti-V5 tag antibody (red) and nuclei were stained with Hoechst 33342 (blue). The
merge of feA3Z2a and Bet staining is shown in the right-hand column. Wt Bet and FFV-PFV CH1 are localized in the cytoplasm (B, E) while
feA3Z2a is localized both in the cytoplasm and the nucleus (A). In some cells coexpressing feA3Z2a and functional Bet proteins, wt Bet and
CH1 relocalize to the nucleus (C, F, G). In other cells, feA3Z2a is recruited to the cytoplasm (D, H). Inserted bars represent 5 μm.
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Figure 11 Colocalization of feA3Z2a with nonfunctional Bet proteins. HeLa cells were transfected with a plasmid encoding HA-tagged
feA3Z2a-HA (A) and/or Bet expression plasmids (B – F), as indicated on the right. feA3Z2a-HA was detected with HA tag-specific antibody
(green), Bet proteins were detected by an FFV Bet-specific serum (red) and nuclei were stained with Hoechst 33342 (blue). The merge of the
feA3Z2a and Bet staining is shown in the right-hand column. Nonfunctional Bet proteins are localized in the cytoplasm (B, D, F) while feA3Z2a is
localized both in the cytoplasm and the nucleus (A). In cells coexpressing feA3Z2a and a nonfunctional Bet mutant, there is no relocalization of
proteins (C, E, G). Inserted bars represent 5 μm.
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incorporated into virions [15,45,47].
Our results show that the Bel2 part of FFV Bet protein
is essential for species-specific feA3Z2b inactivation and
that this domain contains the feA3Z2b interaction site.
In contrast, the Bel1 domain increases protein stabilitybut it is not essential for the A3-inactivating function of
Bet and can be exchanged between PFV and FFV Bet
proteins without detectable loss of function. Alterna-
tively, bel1 RNA sequences or the splice junction may
stabilize the transcripts or induce enhanced cytosolic
protein biosynthesis. There is no sequence homology
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the question of whether the presence of any protein
domain appended to the N-terminus of Bel2ORF would
lead to the same increase of protein stability. However,
since higher amounts of Bel2ORF than wt Bet are
needed for the same level of A3 counteraction (Figure 2),
it might be that the Bel1 domain contributes to anti-A3
activity, for instance, by interacting with some cellular
effector protein.
In line with functional and binding studies, bioinfor-
matics showed that the Bel2 parts of all FVs contain
conserved motifs. Without knowing the protein struc-
ture of Bet, it is difficult to evaluate whether these motifs
are localized on the protein surface and may thus
directly comprise the feA3 binding site. By molecular
modelling using the Robetta full-chain protein structure
prediction server [63,64], we obtained hypothetical three-
dimensional models of Bet. In the most probable model
according to QMEAN and ProQservers [65,66], conserved
motifs 1, 2 and 3, which have been shown here to be abso-
lutely essential for Bet function, are localized on one side
of the Bet protein surface (data not shown). Provided that
this model reflects the real Bet structure, the feA3Z2b
binding domain may consist of a combination of these
motifs. Experimental structure determination of Bet, for
instance by crystallography, is required to solve these is-
sues. For instance, it is currently not known whether EFV
Bet has a similar structure to the other Bet proteins, since
the positions of the second and third conserved motifs are
inverted relative to the other known FVs Bet proteins.
Considering the strong coevolution of FVs with their
hosts including Bet and A3 proteins [2,56], the binding
sites to the species-specific A3 forms may not be con-
served between Bet proteins of different FVs. Alterna-
tively, one can imagine that the A3 binding sites may be
under highly dynamic, positive evolution. Thus, the A3
binding site may be highly divergent and their primary
sequence/structure is likely not maintained. Following
this idea, conserved motifs of Bet may be more import-
ant for maintaining the tertiary structure of Bet and for
proper presentation of the species-specific binding site.
The results of this study support both models, since most
mutations in these motifs and in flanking sequences im-
paired the function of FFV Bet.
There is no start codon that would enable expression
of the full-length motif 1 to 6-containing Bel2 protein
and there is no conserved ATG start coding in the 5′
end of bel2. The first ATG in FFV bel2 is, for instance,
already downstream of the first essential motif, and such
a Bel2-only protein (Bel2ATG) does not have the cap-
acity to protect against A3 editing, as shown here. Since
the bet splice acceptor is located at the 5′end of the bel2
ORF of all FVs examined [49], Bet expression via a
spliced bel1-bel2 fusion transcript allows expression ofall conserved bel2 motifs. This mode of expression may
be an efficient way to generate high amounts of Bet,
since the internal promoter (IP) is very active upon full
transactivation [49]. In addition, Bel1/Tas and Bet ex-
pression via alternative splicing of a single transcription
unit may be an important regulatory mechanism of FV
replication. Through regulated splicing of IP transcripts,
early expression of Bel1/Tas may initiate and maintain
high levels of viral gene expression, while later expres-
sion of Bet protects the viral genome from A3 editing
during and after particle formation and reverse tran-
scription. Expression of Bet during the late phase of
replication and progeny virus production may therefore
be the result of FV evolution to avoid A3 incorporation
into virus particles during replication in A3-positive
cells. It may be even more important for FVs due to the
fact that reverse transcription may already occur in the
virus-producing cells [52].
For all tested mutants, binding to feA3 correlated with
the inactivation of this restriction factor. The tight asso-
ciation between feA3 binding and inactivation by FFV
Bet supports the hypothesis that Bet inactivates A3s by
creating strong complexes [15,45]. This mechanism of
A3 inactivation requires high amounts of Bet proteins
and may be the reason for high expression levels of Bet
in FV-infected cells and animals [48,67,68]. In line with
this, results of this study show that, for efficient inactiva-
tion of A3s, the amount of Bet must be at a sufficiently
high level; small to modest amounts of Bet do not or
only partially counteract A3 restriction.
Hypothetically, binding of Bet to feA3Z2b could mask
the Gag binding site on feA3Z2b, thus preventing its in-
corporation into viral particles. Results presented here
indicate that almost the whole Bel2ORF is important for
feA3Z2b binding and suggest that Bel2ORF may wrap
around feA3Z2b and prevent its interaction with Gag. Al-
ternatively, binding of Bet to A3s could block transport of
A3 into viral particles or interfere with some cellular fac-
tor(s) [15] crucial for A3 packaging into viral particles.
Confocal microscopy indicates that both Bet and
feA3Z2b are apparently uniformly distributed in the
cytoplasm and thus do not allow detection of protein
relocalization upon complex formation. In contrast,
feA3Z2a, which also restricts FFV and is inhibited by
Bet binding [33,47], is also present in the nucleus. Wt
Bet and functional Bet mutants colocalize to the nucleus
in the presence of this restriction factor. Surprisingly, in
some cells, feA3Z2a seems to retarget Bet which is
somewhat counterintuitive since the smaller protein
dictates sub-cellular localization of its larger binding
partner. Why not all cells show this phenotype remains
to be determined.
Bet is a highly expressed viral protein and a diagnostic
marker for FV infection [51,67]. All known FVs express
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for efficient FV replication. Sequences corresponding to
bet/bel2, as determined by localization and sequence
homology, have also been identified in the SloEFV, active
more than 100 million years ago [43], indicating that Bet
is an ancient gene. In addition, a sequence correspond-
ing to bel2 is even present in coelacanth endogenous FV
[50], though it contains only the first conserved motif
(data not shown). This may be a result of the accumula-
tion of mutations from the lack of selective pressure
leading to truncations of the parental bel2 ORF.
Although Bet and Vif counteract A3 restriction fac-
tors, their localization in viral genomes and their fun-
damentally different mechanisms of A3 counteraction
suggest that these two proteins may have evolved inde-
pendently from each other. The ancestral protein(s) of
Vif and Bet may have been cellular A3 binding pro-
teins with regulatory functions. In this model, there
was no need for high level of vif expression in lentivi-
ruses, since Vif acts as an adaptor for a catalytic
degradation of A3 proteins. In contrast, the internal
promoter (IP) of FVs provides high levels of Bet for ef-
ficient inactivation of A3s simply by binding. Alterna-
tively, FVs might have developed an IP to increase the
expression of Bet, since Bet does not recruit the cellu-
lar degradation machinery.Conclusions
The Bel2 domain of FFV Bet contains conserved motifs
and is essential for inactivation of feA3s. Although the
Bel1 part is not directly involved in binding and inacti-
vation of these restriction factors, it is important for
expression of full-length Bel2ORF and protein stability.
The absolute correlation between binding and inactiva-
tion of feA3Z2b by Bet mutants suggests that Bet
inactivates A3s simply by creating strong complexes.
Such a strong feA3Z2b-Bet binding is most probably a
result of a very long coevolution of these two proteins.
Considering that sloth and coelacanth FVs contain
sequences that correspond to bet [43,50] and its con-
served motifs, it is possible that this coevolution be-
tween Bet and A3s or their progenitors extends far back
in vertebrate evolution.Methods
Cell culture and virological methods
HEK293T and FeFab cells were propagated as described
before [69]. HEK293T cells were seeded in 6 cm or
10 cm dishes and transfected using a modified calcium
phosphate method [69]. FFV titers were determined by a
β-galactosidase assay using FFV-FAB (FeFab) cells grown
in 96-well plates [69]. FFV-containing supernatants were
serially diluted 1:5, titrations were done in triplicate.Plasmids and DNA transfection
pFeFV-BBtr and pcfeA3 plasmids have been already
described [33,51,69]. The bacterial expression vector for
glutathione-S-transferase (GST)-tagged feA3Z2b has been
described recently [47].
Molecular cloning of FFV Bet mutants
To construct Bet N-terminal deletion mutants, the cor-
responding bel2 sequences were amplified by Bel2ORF,
Bel2ATG, FFVBetΔN82, or FFVBetΔN92 sense primers
(containing a HindIII site) and FFVbel2as antisense pri-
mer using plasmid pBC-FFV-Bet as template [51]. All
reactions were performed with Phusion™ High-Fidelity
DNA Polymerase (NEB, Germany). Blunt-ended prod-
ucts were digested with HindIII and inserted into
HindIII/SmaI-digested pBC12CMV.
To generate a V5-tagged Bet, bet was amplified with
Bet sense and Bet-V5 antisense primers as above and
cloned into HindIII/SmaI-digested pBC12CMV. To intro-
duce V5 into Bet N-terminal deletion mutants, AccI/XmaI
fragments of pBC-Bel2ORF, pBC-Bel2ATG, pBC-BetΔN82
and pBC-BetΔN92 were replaced by the corresponding
fragment of pBC-FFVBetV5.
V5-tagged C-terminal Bet deletion mutants were con-
structed by amplification of corresponding bet sequences
with Bet sense and one of three different antisense
primers (dC1-V5, dC2-V5 or dC3-V5, Table 1) with a V5
epitope. PCR products were cloned into HindIII/SmaI-
digested pBC12CMV.
To construct chimeric Bet proteins, corresponding
parts of PFV and FFV bet were fused in-frame by fusion
PCR [70]. Corresponding parts of each gene were ampli-
fied in individual PCR reactions. For instance, for clon-
ing of FFV-PFV CH1, PCR1 with chimera-s1 and ch1-as
using pBC-FFV-Bet as template and PCR2 with ch1-s2
and Bet V5 as primers and pBC-PFV-Bet as template were
performed as given above. Finally, the amplicons were fused
in PCR3 using chimera-s1 and Bet-V5 antisense primers.
Blunt-ended PCR products were digested with HindIII and
cloned into HindIII/SmaI-digested pBC12CMV. To con-
struct FFV-PFV CH7 to CH11, FFV Bet was amplified with
generic ch-sense1-bspe1 and a mutant-specific as1 primer.
PFV Bet was amplified with the corresponding s2 primer
and generic chimera-as primer. Products of both PCRs
were fused in a third PCR reaction with ch-sense1-bspeI
and chimera-as primers. Final products were cloned into
BspEI/SmaI digested pBC-Bet-V5.
Alanine scanning mutagenesis of the second conserved
motif of FFV Bet and flanking residues was performed
by amplifying bet between the unique HindIII and KpnI
sites using Bet-sense and one of three antisense primers
(BetAlaRI, BetAlaRII, BetAlaRIII for ΔELL, ΔLTR and
ΔLTM, respectively). Products were cloned into HindIII/
KpnI-digested pBC-Bet. Residues downstream of KpnI
Table 1 Primers used for cloning and site-directed mutagenesis
Name Sequence (5′-3′ direction)
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Table 1 Primers used for cloning and site-directed mutagenesis (Continued)
dSW-AS1 CTCTTTGGCAGCGGCCACCCTCTCCTCACTGTTCC
dSW-S2 GCCGCTGCCAAAGAGAATTCTCACAGAG
AS2-XmaI AGTGTAAGTTCACCCGGGTCACTCGAGCTATTCAGAGTCAGATGACTC (SmaI, XmaI)


























All primer sequences are in the 5′ to 3′ orientation. Sequences in italics correspond to restriction enzyme recognition sites that were used for cloning; the names
of the enzymes are given in brackets. Underlined sequences mark the mutations introduced. Sequences encoding the V5 tag are given in bold-face letters.
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sense primers (BetAlaFI, BetAlaFII and BetAlaFIII for
ΔGIG, ΔLVQ and ΔI, respectively) and BetAlaR2 as gen-
eral antisense primer. Products were cloned into pBC-
Bet with KpnI and AccI. Using V, P, or VP sense primers,
the BetAlaR antisense primer, and Bet-XhoI (in which an
XhoI site was silently introduced with Bet sense and R-
XhoI antisense primer) as template, corresponding parts
of Bet were amplified and the indicated codons ex-
changed by alanine codons. PCR products were cloned
into pBC-Bet-XhoI using XhoI and AccI.
Residues in the first, third and fifth conserved motifs
were exchanged by fusion PCR. Bet was amplified with
Bet-sense and AS1 antisense primers. The second PCR
was performed with S2 sense primers and AS-XmaI pri-
mer, covering the bet stop codon and carrying an XmaIsite (e. g. fusion PCR with Bet-sense, dGPL-AS1, dGPL-S2,
AS-XmaI primers for ΔGPL). The two fragments were
fused by PCR using Bet-sense and AS-XmaI. The final
product was cloned into pBC12-CMV using HindIII
and XmaI.
Coimmunoprecipitation (co-IP) and immunoblotting
To study the interaction between proteins expressed in
eukaryotic cells, HEK293T cells were seeded in 10 cm
dishes and transfected with 6 μg of pcfeA3Z2b-HA and
12 μg of PFV Bet, FFV Bet, or chimeric FFV/PFV Bet
expression plasmid. Two d.p.t., cells were lysed in TLB
(20 mM Tris, pH 7.4, 137 mM NaCl, 10% glycerol, 2 mM
EDTA, 1% Triton X-100 and protease inhibitor). Lysates
were cleared by 5 min centrifugation at 500 × g. 100 μl of
the cell lysate was incubated with monoclonal mouse anti-
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overnight at 4°C. The beads were washed three times in
TLB. After the last wash, beads were boiled in sample
buffer and precipitated proteins were detected by im-
munoblotting. feA3Z2b-HA was detected with monoclo-
nal anti-HA IgG (Abcam). PFV Bet was detected with
PFV Bet-specific serum. Wt FFV Bet and chimeric pro-
teins were detected with monoclonal mouse anti-V5
IgG (Sigma-Aldrich, Munich, Germany). Membranes
were incubated with horseradish peroxidase-conjugated
secondary antibodies (Sigma-Aldrich) and visualized by
enhanced chemiluminescence (ECL, GE Healthcare,
Freiburg, Germany). Densitometry was performed of
scanned autoradiograms using the ImageJ software [71].
Immunofluorescence and confocal microscopy
HeLa cells were grown on coverslips in 6-well plates and
transfected with 1 μg feA3Z2b and feA3Z2a expression
plasmids and 2 μg of plasmid expressing wt or mutant
Bet. 2 d.p.t., cells were fixed with 3% paraformaldehyde
in PBS for 15 min. and permeabelized with 0.1% Triton-
X-100 for 7 min. Cells were incubated with rabbit FFV
Bet-specific serum (1:1000) and monoclonal mouse anti-
HA IgG (Abcam) diluted in 3% BSA in PBS. Alexa Fluor®
488 goat anti-mouse IgG and Alexa Fluor® 594 goat anti-
rabbit IgG (both from Invitrogen, Karlsruhe, Germany)
were used as secondary antibodies in a dilution of 1:2000.
Nuclei were stained with Hoechst 33342 (1:2000). Cells
were imaged using a Zeiss LSM700 confocal microscope
(Zeiss, Jena, Germany).
Protein pulldown assays
For pull down assays of the feA3 with FFV-Bet, HEK293T
cells were transfected with 10 μg of FFV Bet expression
plasmids. Two d.p.t., cells were lysed in 250 μl TLB and
lysates were cleared by centrifugation. 100 μl of cleared
supernatants were incubated with approximately one
mg GST-feA3Z2b fusion proteins purified by glutathione-
S-sepharose affinity chromatography according to the
manufacturer’s instruction (GE Healthcare, UK) as de-
scribed previously [47]. Samples were incubated overnight
at 4°C and washed three times with TLB. As negative con-
trol, samples were incubated with GST alone. Samples
were boiled in sample loading buffer and separated and
probed by SDS-PAGE and immunoblotting.
Bioinformatics
Conserved motives in Bet were identified using MEME
(Multiple Expectation maximization for Motif Elicitation
[57]). MEME is an unsupervised learning algorithm for
discovering motifs in sets of protein or DNA sequences
that quantifies/predicts the chance of interchangeability
of defined residues in related sequences [57].DNA and protein sequence analysis were performed
using Geneious and ClustalW2. Molecular models of
FV Bet were obtained using the Robetta Protein Predic-
tion Server (http://robetta.bakerlab.org) [63,64]. Pre-
dicted models were evaluated using the QMEAN and
ProQ servers [65,66].Additional files
Additional file 1: N-terminal deletion mutants are detected to
similar degrees by the Bet-specific serum and a V5 tag-specific
antibody. HEK293T cells were transfected with 5 μg of pBC-Bet-V5, pBC-
Bel2ORF-V5, pBC-Bel2ATG-V5, pBC-BetΔN82-V5 or pBc-BetΔN92-V5 and
harvested 2 d. p.t. 40 μg of proteins from each cell lysate was used for
protein detection. Two SDS gels were used for immunoblotting and one
membrane was incubated with the FFV Bet-specific serum (A) and the
other with the V5-specific antibody (B). The wt and mutant Bet proteins
were detected with similar efficacy using both Bet-specific serum and V5
tag-specific antibody.
Additional file 2: C-terminal Bet deletion mutants do not
counteract feA3Z2b-mediated restriction. (A) Schematic presentation
of full-length Bet and C-terminal Bet deletion mutants. Grey boxes
represent conserved motifs and green boxes represent V5 tags. (B)
HEK293T cells were cotransfected with 4 μg of pCF-BBtr and pcDNA or
pfeA3Z2b-HA and 5 μg of plasmids expressing wt Bet or Bet C-terminal
deletion mutants, as indicated. One d.p.t., ALLN (25 μM) or DMSO was
added to the cells. Two d.p. t., titration was performed in triplicate and
mean titer values are presented. Error bars represent standard deviations.
Labels below the columns indicate the clone that was cotransfected. The
line above the columns indicates the presence of feA3Z2b. Bet and Bet-
V5 efficiently restored viral titer in the presence of ALLN. C-terminal Bet
deletion mutants did not restore viral titer, although expression levels
increased in the presence of ALLN. (C) 40 μg of proteins from each cell
lysate were used for immunoblot analysis. Wt and mutant Bet were
detected either with V5-specific antibody or an FFV Bet serum. Levels of
C-terminal deletion mutants partially increased in the presence of ALLN,
while levels of the other proteins were unchanged. HA tag-specific
antibody was used for feA3Z2b-HA detection, an FFV MA serum for Gag
detection, and detection of β-actin confirmed proper loading of the
samples. (D) HEK293T cells were transfected with 10 μg of pBC-Bet
ΔC244-V5, pBC-BetΔC292-V5, pBCBetΔC357-V5 or pBC-Bet-V5. Protein
expression increased by supplementing cell culture medium with 8 mM
sodium butyrate. Two d.p.t., cells were lysed and incubated with affinity-
purified GST or GST-feA3Z2b. Pulled down proteins were detected by
immunoblotting with V5-specific antibody. Hatched lines mark empty gel
lanes to separate individual assays. Only full-length Bet-V5 was pulled
down with GST-feA3Z2b. The presence (+) or the absence (−) of GST and
GST-A3Z2b are indicated; CL, cell lysate.
Additional file 3: Site-directed mutagenesis of conserved FFV Bet
motifs 1 to 3 impair Bet function. HEK293T cells were cotransfected
with pCF-BBtr and pcDNA or pfeA3Z2b and plasmid expressing wt or
mutant FFV Bet proteins as indicated. (A, B, C) Two d.p.t., titration was
performed in triplicate using FeFab cells and mean values are
represented; error bars represent standard deviation. The line above the
graph indicates the presence of feA3Z2b. Black dots on white bars
indicate motif 1 mutants; hatched bars, motif 2 mutants; striped bars,
motif 3 mutants; white dots on black bars, motif 5 mutants; black bars,
wt Bet; white bars, pcDNA (see also Figure 8). In the presence of
feA3Z2b, the FFV-BBtr titer decreased 3 to 4 logs. FFV Bet, used as a
positive control restored the viral titer in all cases. None of the Bet
proteins with mutations in the first conserved motif were functionally
active, although there were minor variations of the titer. BetΔDPD is the
only mutant with substitutions in the third conserved motif that was
functionally active. All mutants with substituted amino acids in the fifth
conserved motif counteracted feA3Z2b-mediated FFV-BBtr restriction
with slightly reduced efficacies (D, E, and F). 40 μg of proteins from each
cell lysate were used for immunoblot analysis. Wt and mutant Bet
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antibody was used for feA3Z2b-HA detection, MA serum for Gag
detection, and β-actin as a loading control.
Additional file 4: Bet proteins with mutations in conserved motifs
1–3 cannot bind feA3Z2b. HEK293T cells were transfected with 10 μg
of wt or mutant Bet expression plasmids. Two d.p.t., cells were lysed and
incubated with affinity-purified GST or GST-feA3Z2b. After overnight
incubation, pulled down proteins were detected by immunoblotting with
FFV Bet-specific serum. Hatched lines mark empty gel lanes to separate
individual pulldown assays. The presence (+) or the absence (−) of GST
and GST-A3Z2b are indicated. The upper panel shows pull down assays
performed with Bet mutants carrying mutations in the second conserved
motif. Pulldown assays with mutations in the first, third or fifth conserved
motif of Bet are boxed.
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